clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Pseudomyxoma Peritonei D011553 1 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Prurigo D011536 4 associated lipids
Proteinuria D011507 30 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pleural Diseases D010995 4 associated lipids
Periodontitis D010518 22 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontal Abscess D010508 2 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Peptic Ulcer D010437 19 associated lipids
Parotitis D010309 4 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Parotid Diseases D010305 1 associated lipids
Paronychia D010304 3 associated lipids
Parkinson Disease D010300 53 associated lipids
Pancreatitis D010195 10 associated lipids
Pain D010146 64 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Otitis Media D010033 12 associated lipids
Osteomyelitis D010019 10 associated lipids
Psittacosis D009956 4 associated lipids
Endophthalmitis D009877 12 associated lipids
Nocardia Infections D009617 6 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nasal Polyps D009298 26 associated lipids
Myxoma D009232 1 associated lipids
Myocardial Infarction D009203 21 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Metaplasia D008679 7 associated lipids
Mastoiditis D008417 2 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Mycetoma D008271 4 associated lipids
Lymphangitis D008205 4 associated lipids
Lymphadenitis D008199 8 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Lung Diseases D008171 37 associated lipids
Leprosy D007918 8 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Klebsiella Infections D007710 7 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Ischemia D007511 18 associated lipids
Iritis D007500 2 associated lipids
Iris Diseases D007499 2 associated lipids
Insulin Resistance D007333 99 associated lipids
Influenza, Human D007251 11 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Hypoproteinemia D007019 1 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Hypercholesterolemia D006937 91 associated lipids
HIV Seropositivity D006679 15 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Hemophilia A D006467 10 associated lipids
Hemolysis D006461 131 associated lipids
Heart Failure D006333 36 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Hearing Disorders D006311 10 associated lipids
Hand Dermatoses D006229 5 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Giardiasis D005873 3 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Gastritis D005756 27 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Fractures, Open D005597 3 associated lipids
Foot Diseases D005534 4 associated lipids
Fistula D005402 8 associated lipids
Fibrosis D005355 23 associated lipids
Fever D005334 35 associated lipids
Exanthema D005076 11 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Erythema Nodosum D004893 5 associated lipids
Ergotism D004881 4 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Endometriosis D004715 29 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Encephalitis D004660 15 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Empyema D004653 3 associated lipids
Ecchymosis D004438 3 associated lipids
Dyspnea D004417 10 associated lipids
Dyspepsia D004415 5 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Duodenitis D004382 4 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Funke G et al. Development of resistance to macrolide antibiotics in an AIDS patient treated with clarithromycin for Campylobacter jejuni diarrhea. 1994 Eur. J. Clin. Microbiol. Infect. Dis. pmid:7805694
Fujii R et al. [Clinical studies on clarithromycin dry syrup in the pediatric field. Pediatric Study Group of TE-031 Dry Syrup]. 1994 Jpn J Antibiot pmid:7807690
Bonnet E et al. Clarithromycin: a potent agent against infections due to Mycobacterium marinum. 1994 Clin. Infect. Dis. pmid:8038339
Lemmen SW et al. Bactericidal activity of clarithromycin and cefaclor against Streptococcus pneumoniae and Moraxella catarrhalis in healthy volunteers. 1994 J. Antimicrob. Chemother. pmid:8040139
Labenz J et al. [Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?]. 1994 Leber Magen Darm pmid:8196468
Chan GP et al. Clinical trial of clarithromycin for lepromatous leprosy. 1994 Antimicrob. Agents Chemother. pmid:8203847
Onyeji CO et al. Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages. 1994 Antimicrob. Agents Chemother. pmid:8203849
Jones RN et al. Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards. 1994 Diagn. Microbiol. Infect. Dis. pmid:7924221
Kanatani MS and Guglielmo BJ The new macrolides. Azithromycin and clarithromycin. 1994 West. J. Med. pmid:8128699
Verbist L and Dhoore F In vitro susceptibility of recently isolated respiratory tract pathogens to minocycline and comparable antibiotics. A multicentre study. 1994 Acta Clin Belg pmid:7871933
Ji B et al. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. 1994 Antimicrob. Agents Chemother. pmid:7872741
Tessier MH et al. Clarithromycin for atypical mycobacterial lymphadenitis in non-immunocompromised children. 1994 Dec 24-31 Lancet pmid:7997032
Mor N et al. Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. 1994 Jan-Feb Pharmacotherapy pmid:8159593
Winter J Intravenous clarithromycin. 1994 Mar 16-Apr 5 Br J Hosp Med pmid:8032567
Gersema LM et al. Suspected drug interaction between cyclosporine and clarithromycin. 1994 Mar-Apr J. Heart Lung Transplant. pmid:8031821
Heifets LB Quantitative cultures and drug susceptibility testing of Mycobacterium avium clinical isolates before and during the antimicrobial therapy. 1994 Mar-Apr Res. Microbiol. pmid:7809471
Dautzenberg B Clinical trials in Mycobacterium avium therapy: lessons to take home. 1994 Mar-Apr Res. Microbiol. pmid:7809472
Scaglione F et al. Effect of antibiotics on Bordetella pertussis adhering activity: hypothesis regarding mechanism of action. 1994 May-Jun Chemotherapy pmid:7515782
O'Connor NK and Fris J Clarithromycin-carbamazepine interaction in a clinical setting. 1994 Nov-Dec J Am Board Fam Pract pmid:7847111
Cama VA et al. Treatment of acute and chronic Cryptosporidium parvum infections in mice using clarithromycin and 14-OH clarithromycin. 1994 Sep-Oct J. Eukaryot. Microbiol. pmid:7804227
Adamek RJ et al. Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection. 1995 Am. J. Gastroenterol. pmid:7801936
FDA approves Biaxin for MAC prophylaxis. Food and Drug Administration. 1995 J Int Assoc Physicians AIDS Care pmid:11363096
Jaup BH and Norrby A Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. 1995 Am. J. Gastroenterol. pmid:7771426
Ives DV et al. Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. 1995 AIDS pmid:7755914
Block S et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. 1995 Pediatr. Infect. Dis. J. pmid:7667050
Nash KA and Inderlied CB Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. 1995 Antimicrob. Agents Chemother. pmid:8592991
Klapper SR et al. Atypical mycobacterial infection of the orbit. 1995 Ophthalmology pmid:9097803
Savarino V et al. What is the meaning of ranitidine in successful triple-therapy against Helicobacter pylori infection? 1995 Am. J. Gastroenterol. pmid:8540537
Gustavson LE et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. 1995 Antimicrob. Agents Chemother. pmid:8540719
Ostroff SM et al. Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. 1995 Clin. Infect. Dis. pmid:8547516
Odagiri S Levofloxacin in patients with severe respiratory tract infection. 1995 Drugs pmid:8549387
Logan RP et al. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. 1995 Aliment. Pharmacol. Ther. pmid:8527618
Lee D et al. Localized Mycobacterium avium-intracellulare mastitis in an immunocompetent woman with silicone breast implants. 1995 Plast. Reconstr. Surg. pmid:7809228
Gill CJ et al. In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin. 1995 J. Antibiot. pmid:7490222
Adamek RJ et al. [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection]. 1995 Dtsch. Med. Wochenschr. pmid:7889816
Spangler SK et al. Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by oxyrase agar dilution and E test methodologies. 1995 J. Clin. Microbiol. pmid:7615756
Vance E et al. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. 1995 Antimicrob. Agents Chemother. pmid:7574530
Singh N and Yu VL Clarithromycin therapy for Mycobacterium avium complex bacteremia. 1995 Ann. Intern. Med. pmid:7632282
Michałowska-Mitczuk D [Patients with chronic sputum positive tuberculosis-a therapeutic problem]. 1995 Pneumonol Alergol Pol pmid:7633360
Colizza DF Pertussis update. 1995 J Sch Health pmid:7637337
de Boer WA and Tytgat GN The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? 1995 Scand. J. Gastroenterol. pmid:7638563
Takimoto T et al. Efficacy of lansoprazole in eradication of Helicobacter pylori. 1995 J. Clin. Gastroenterol. pmid:7594327
Shimoyama T et al. Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. 1995 J. Clin. Gastroenterol. pmid:7594328
Fukuda Y et al. Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. 1995 J. Clin. Gastroenterol. pmid:7594330
Xu G et al. [Effect of clarithromycin on macrophage functions]. 1995 Kansenshogaku Zasshi pmid:7594777
Gelber RH et al. Activity of combinations of dapsone, rifampin, minocycline, clarithromycin, and sparfloxacin against M. leprae-infected mice. 1995 Int. J. Lepr. Other Mycobact. Dis. pmid:7602221
Milde P et al. Cutaneous bacillary angiomatosis in a patient with chronic lymphocytic leukemia. 1995 Arch Dermatol pmid:7543264
Nightingale SD et al. Clarithromycin-induced mania in two patients with AIDS. 1995 Clin. Infect. Dis. pmid:7548513
Matsiota-Bernard P et al. Mycobacterium genavense infection in a patient with AIDS who was successfully treated with clarithromycin. 1995 Clin. Infect. Dis. pmid:7548515
Citron DM et al. Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children. 1995 Clin. Infect. Dis. pmid:7548597
Ishii K et al. A new pharmacokinetic model including in vivo dissolution and gastrointestinal transit parameters. 1995 Biol. Pharm. Bull. pmid:7550125
Harris AW et al. Eradication of Helicobacter pylori with lansoprazole and clarithromycin. 1995 Aliment. Pharmacol. Ther. pmid:7605863
Katelaris PH et al. A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. 1995 Aliment. Pharmacol. Ther. pmid:7605864
Tamaoki J et al. Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. 1995 J. Allergy Clin. Immunol. pmid:7722166
Conte JE et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. 1995 Antimicrob. Agents Chemother. pmid:7726492
Lacassin F et al. Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. 1995 Antimicrob. Agents Chemother. pmid:7695324
Labenz J and Börsch G Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. 1995 Am. J. Gastroenterol. pmid:7733070
Forné M et al. Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. 1995 Am. J. Gastroenterol. pmid:7733075
Tebas P et al. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. 1995 Clin. Infect. Dis. pmid:7742453
Teare JP et al. Pseudomembranous colitis following clarithromycin therapy. 1995 Eur J Gastroenterol Hepatol pmid:7743311
Pollak PT et al. Delirium probably induced by clarithromycin in a patient receiving fluoxetine. 1995 Ann Pharmacother pmid:7655131
Ozmen MM and Johnson CD Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? 1995 Am. J. Gastroenterol. pmid:7661197
Cahill RJ et al. Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation. 1995 Dig. Dis. Sci. pmid:7648960
Dautzenberg B et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. 1995 Chest pmid:7705112
Schlossberg D Azithromycin and clarithromycin. 1995 Med. Clin. North Am. pmid:7791424
Gross RH et al. Corneal pharmacokinetics of topical clarithromycin. 1995 Invest. Ophthalmol. Vis. Sci. pmid:7706046
Frotz H et al. [Ranitidine and clarithromycin for eradication of Helicobacter pylori in patients with duodenal ulcer]. 1995 Arzneimittelforschung pmid:7710445
Luna-Herrera J et al. Antituberculosis activity of clarithromycin. 1995 Antimicrob. Agents Chemother. pmid:8593004
Ellis LC et al. Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. 1995 Antimicrob. Agents Chemother. pmid:8593025
Truffot-Pernot C et al. Clarithromycin is inactive against Mycobacterium tuberculosis. 1995 Antimicrob. Agents Chemother. pmid:8593032
Schütze K and Hentschel E Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. 1995 Z Gastroenterol pmid:8600661
Tseng AL and Walmsley SL Rifabutin-associated uveitis. 1995 Ann Pharmacother pmid:8573961
Moayyedi P et al. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. 1995 Eur J Gastroenterol Hepatol pmid:8574714
Fujioka T et al. Peptic ulcer recurrence after Helicobacter pylori eradication: a 5-year follow-up study. 1995 Eur J Gastroenterol Hepatol pmid:8574733
Deltenre M et al. Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. 1995 Eur J Gastroenterol Hepatol pmid:8574734
Rizzato G et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. 1995 Eur. Respir. J. pmid:7789484
Gidoh M and Saito H [Present status of studies on antileprosy drugs]. 1995 Nihon Rai Gakkai Zasshi pmid:8582877
Stafstrom CE et al. Erythromycin-induced carbamazepine toxicity: a continuing problem. 1995 Arch Pediatr Adolesc Med pmid:7827672
Labenz J et al. High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. 1995 Digestion pmid:7895926
Reid R et al. Pneumococcal meningitis during therapy of otitis media with clarithromycin. 1995 Pediatr. Infect. Dis. J. pmid:8786899
Van Asselt GJ et al. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro. 1995 J. Med. Microbiol. pmid:7563004
Clarithromycin for MAC. 1995 AIDS Patient Care pmid:11361361
Wallace RJ et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. 1995 J. Infect. Dis. pmid:7876634
Moorthy RS and Rao NA Atypical mycobacterial wound infection after blepharoplasty. 1995 Br J Ophthalmol pmid:7880802
Yoshizawa A et al. [Legionella pneumonia diagnosed by urinary antigen detection]. 1995 Nihon Kyobu Shikkan Gakkai Zasshi pmid:7791279
Cheng B Preventing opportunistic infections. 1995 PI Perspect pmid:11362422
Lounis N et al. Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. 1995 Antimicrob. Agents Chemother. pmid:7793860
Fattorini L et al. In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. 1995 Antimicrob. Agents Chemother. pmid:7793873
Abbott files SNDA for MAC prophylaxis. 1995 J Int Assoc Physicians AIDS Care pmid:11362606
Cohen Y et al. Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity. 1995 Antimicrob. Agents Chemother. pmid:7793882
Pierce M Another perspective on MAC prophylaxis. Interview by Gordon Nary. 1995 J Int Assoc Physicians AIDS Care pmid:11362746
Furney SK et al. Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. 1995 Antimicrob. Agents Chemother. pmid:7793895
Archange YR et al. Clarithromycin prophylaxis against disseminated Mycobacterium avium complex in patients with AIDS. 1995 J Int Assoc Physicians AIDS Care pmid:11362747
Brown BA et al. Clarithromycin-induced hepatotoxicity. 1995 Clin. Infect. Dis. pmid:7795060
Physician's aggressive preventive therapy differs. 1995 AIDS Alert pmid:11362774
Raffi F et al. Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin. 1995 Clin. Infect. Dis. pmid:7795062
New drug applications sought. 1995 AIDS Alert pmid:11362777
Smart T Cryptosporidiosis at ICAAC. 1995 GMHC Treat Issues pmid:11362913
Sharma PK and Tami TA AIDS: lessons from the last decade and prospects for the future. 1995 Ear Nose Throat J pmid:7796740
Researchers find new drugs to fight MAC. 1995 AIDS Alert pmid:11362925